



VOLUME 17
NUMBER 12
DECEMBER 2013
SUPPLEMENT 2

PAGES S1–S564
ISSN 1027 3719

The International Journal of Tuberculosis and Lung Disease

The Official Journal of the International Union Against Tuberculosis and Lung Disease

ABSTRACT BOOK

**44th World Conference
on Lung Health of the
International Union Against
Tuberculosis and Lung Disease (The Union)**

**PARIS • FRANCE
30 OCTOBER–3 NOVEMBER 2013**

S1 PLENARY SESSIONS

SYMPOSIA

FRIDAY 1 NOVEMBER 2013

- S3 Critical issues and challenges for maximising the impact of Xpert® MTB/RIF
- S4 Preventing HIV-related tuberculosis at the community level: a synthesis of the CREATE studies
- S5 Tuberculosis reinfection: impact on tuberculosis control
- S6 Improved tuberculosis diagnostics adding new dynamics to tuberculosis control
- S7 How can tobacco control strategies improve HIV and tuberculosis patient outcomes?
- S9 Climatic change and environmental air pollution: our rightful concern
- S9 Tuberculosis and environmental migrants: preparedness and response to migration in disasters
- S11 Reducing second-hand smoke exposure in the home
- S13 Child pneumonia: new evidence and new possibilities to reduce child mortality
- S13 MDR-TB in children and adolescent tuberculosis issues
- S15 Towards safer air: differing approaches to reducing the risk of tuberculosis transmission in HIV clinical settings
- S16 Translating *Mycobacterium tuberculosis* molecular diagnostics into clinical management
- S19 'Man does not live by bread alone'. Effects of nutritional support for tuberculosis patients in tuberculosis treatment outcomes
- S20 Tuberculosis control in prisons: safer environments for incarcerated populations
- S22 Healthy lungs, healthy children: using advocacy to improve child lung health
- S22 Educational and behaviour change approaches towards tobacco control: a growing need
- S23 Zoonotic tuberculosis: still a public health challenge

SATURDAY 2 NOVEMBER 2013

- S26 Recent progress in tuberculosis clinical trials
- S26 Optimising tuberculosis control in high HIV prevalence settings
- S28 Accelerating scale-up: rapid amplification of PMDT capacity
- S30 Rolling-out LED fluorescence microscopy: yield and challenges
- S31 Airborne data: opportunities for electronic health to improve tuberculosis care and lung health
- S33 Measuring the contribution of ACSM to increased tuberculosis case detection and improved treatment outcomes
- S35 Feasibility of supply-side measure for tobacco's endgame
- S36 Diagnostic and therapeutic challenges for latent tuberculosis infection
- S37 Engaging pharmacists for tuberculosis control: rhetoric or reality?
- S39 Can new diagnostic tools reduce the time to appropriate tuberculosis treatment initiation?
- S41 Rational drug use for MDR-TB: start safe, stay safe, breathe safe
- S42 What do we know about the tuberculosis burden in globally mobile populations? The latest global evidence

- S43 Strategies for social support: navigating through the complexity of care to tuberculosis patients
- S46 Economic burden of tuberculosis: study cases and policy implementation
- S48 Tuberculosis in the mining sector: politics, policy and practice
- S49 Catalysing the pediatric tuberculosis drug market: a call to action

SUNDAY 3 NOVEMBER 2013

- S51 HIV, tuberculosis and human rights and the law
- S52 Contact investigation: operational research to increase case detection and improve the safety of shared air
- S52 A, C, G, TB: insights into tuberculosis epidemiology and evolution from whole genome sequencing
- S54 Effective tuberculosis education and communication interventions for providers and patients
- S56 Childhood tuberculosis diagnostics: we have made progress, but are we there yet?
- S59 Controversies in tuberculosis: short course chemotherapy for all as a strategy to eliminate tuberculosis in a South Pacific island
- S59 Tobacco cessation and smoke-free environment for tuberculosis patients in low-income countries
- S61 Shared air, but not necessarily safe air: tuberculosis infection control in out-patient and congregate settings
- S61 Smoke-free environments: using compliance testing as a tool to improving population lung health overall
- S63 Best practices in implementing TB-HIV collaborative activities in maternal and child health settings
- S64 Innovative approaches to bringing new tuberculosis diagnostics to the private sector
- S65 Communities with a heavy burden of tuberculosis imposed by poverty and marginalisation
- S65 Getting to Zero: a roadmap for eliminating childhood tuberculosis
- S66 Unsafe air: where does it happen, how should it be managed and what are the ethical implications?
- S67 Improving tuberculosis case detection in sub-Saharan African health systems: from communities to tertiary hospitals

ABSTRACT PRESENTATIONS

FRIDAY 1 NOVEMBER 2013

Oral presentation sessions

- S68 Implementation of GeneXpert® MTB/RIF
- S73 Advances in AFB microscopy and rapid culture methods
- S77 Civil society perspective on tuberculosis control
- S82 Hand in hand: screening for tuberculosis and HIV
- S86 The evolving epidemiology of tuberculosis in children
- S90 Innovations in studying the transmission of tuberculosis
- S95 Factors impacting diagnosis, treatment and sputum distribution of tuberculosis
- S99 Tuberculosis research from the bench to programme outcomes
- S103 Assessing knowledge, attitudes and practice in the treatment of tuberculosis

Poster discussion sessions

- S109 Holding hands together: linking TB-HIV collaboration
- S114 A potpourri of tuberculosis and HIV issues
- S118 New insights into the epidemiology of tuberculosis in children
- S124 Developments in the diagnosis of tuberculosis in children
- S129 Floods, migrants, camps: innovations in tuberculosis patient care
- S133 Tuberculosis contact investigations
- S138 Molecular diagnostic tests for tuberculosis
- S142 Improve tuberculosis case detection innovation
- S147 Information technology to improve tuberculosis control
- S155 Drug considerations in the treatment of tuberculosis
- S161 Clinical issues and tuberculosis
- S166 MDR-TB: management in special populations
- S172 PPM, partnerships, collaboration
- S179 Reaching the unreachable: the role of civil society in tuberculosis
- S185 Expanding the Stop TB Strategy
- S192 Empowering patients in the fight against tuberculosis
- S198 Tuberculosis control among vulnerable populations**
- S203 Improved case detection using GeneXpert® MTB/RIF
- S211 Drug resistance: genes and surveys
- S216 Ensuring quality of tuberculosis laboratory services
- S221 Advances in tuberculosis culture methods
- S226 Tobacco burden, surveillance and programme implementation

SATURDAY 2 NOVEMBER 2013

Oral presentation sessions

- S234 MDR-TB: clinical course, reversions, acquired drug resistance
- S237 The promise of life: initiating HIV treatment
- S242 Inextricably linked: integrating tuberculosis and HIV care
- S246 Parts of a whole: drugs, dosing and morbidity in TB-HIV
- S251 Novel concept in the diagnosis and treatment of tuberculosis and children
- S255 Determinants of lung health and disease
- S259 Improving the management of tuberculosis: drug tools, X-rays and surgery
- S265 People living without liberty: case finding and holding in prisons
- S269 Advances in culture methods

Poster discussion sessions

- S274 Serodiagnostics and biomarkers
- S279 Country, community and flash in tuberculosis: the role of civil society
- S286 A two-way street: testing and screening for tuberculosis and HIV
- S292 Outbreaks and immunology in childhood respiratory diseases
- S297 Global issues in lung health
- S302 Tuberculosis control among vulnerable populations: prisoners and miners
- S308 AFB smear microscopy
- S311 Developing human capacity to improve tuberculosis control
- S316 Tuberculosis molecular epidemiology
- S322 Food for thought: nutrition and other issues
- S326 Managing tuberculosis: from epidemiology to treatment

- S330 Medical management of tuberculosis
- S335 MDR-TB: from research to practice
- S338 Managing tuberculosis public-private relationships
- S343 Increasing case finding process, PPM, partnerships, laboratory diagnosis
- S350 Tuberculosis infection control
- S357 Tuberculosis control public policy
- S364 Tuberculosis surveillance, including bovine tuberculosis
- S372 Prevalence of tuberculosis and diabetes mellitus around the world
- S378 Programmatic issues in tuberculosis control programmes
- S385 Who is at risk with tuberculosis?
- S391 Partnerships in tuberculosis control

SUNDAY 3 NOVEMBER 2013

Oral presentation sessions

- S396 Upfront and close: contact investigations among the high risk
- S398 Molecular diagnostics for tuberculosis
- S401 Babies, mothers, adolescents and stigma: family issues in TB-HIV
- S404 Identifying barriers to the treatment and prevention of tuberculosis in children
- S407 Human capacity development: the basis of good programmes
- S409 Tuberculosis in the workplace
- S412 Around the world with tuberculosis and diabetes mellitus
- S415 Exploring tuberculosis risk factors
- S418 Tobacco control: advocacy and programme implementation

Poster discussion sessions

- S421 FCTC, MPOWER and tobacco control policies
- S429 Treatment equals prevention for tuberculosis and HIV
- S434 Operational challenges in child lung health
- S440 Transmission and treatment of childhood tuberculosis
- S445 Tuberculosis case finding among vulnerable populations
- S450 Tuberculosis costs and collaboration issues
- S458 Tuberculosis case finding
- S467 Community issues in tuberculosis control
- S471 MDR-TB diagnosis
- S478 Drug resistance surveillance
- S486 Regional and country approaches to MDR-TB management
- S495 Finding, screening and recording cases of drug-resistant tuberculosis
- S502 Tuberculosis diagnostics: IGRAs
- S505 Spatial and temporal tuberculosis distribution
- S514 Tuberculosis molecular epidemiology and genotyping
- S517 Tuberculosis treatment/medical management/ programme
- S524 Tuberculosis basic science laboratory
- S529 Treating drug-resistant tuberculosis: challenges and solutions
- S536 Performance of the GeneXpert® MTB/RIF assay
- S541 Assessing knowledge, attitudes and practice in the treatment of tuberculosis
- S548 MDR surveillance
- S554 Tobacco cessation
- S559 Drug-resistant tuberculosis: clinical and programmatic aspects

referred to the nearest Designated Microscopy Cen-ter (DMC) or their sputum was collected and trans-ported to the DMC and those found to be TB were started on DOTS medicines as per the program treat-ment guidelines.

Results and lessons learnt: Of 1606 slum population and 1420 refugees visited, 43 (2.7%) and 34 (2.4%) were found to have cough for more than 2 weeks. Of them, 38 (88%) and 32(94%) got themselves tested and 4 and 3 sputum positive pulmonary TB were subsequently started on treatment.

Conclusions and key recommendations: The above findings highlight the importance and necessity of conducting periodic outreach activities among the vulnerable (slum) and marginalized (refugees) popu-lation. These groups usually have lack/limited access to TB diagnostic services. Seeking diagnosis for their symptoms could receive low priority for these popu-lations who encounter other social challenges, result-ing in delayed diagnosis and worsening of the disease. The above activities resulted in early diagnosis among these groups which would help in reducing the trans-mission in the community. The process served to reach across to these populations with basics of TB and facilitated linkages of these communities with the health system.

PC-482-01 Tuberculosis among the Roma population in Macedonia

M Trajcevska, A Sandevski, Lj Simonovska. Clinical Sector, Institute of Lung Diseases and Tuberculosis, Skopje, Macedonia, Yugoslav Republic. e-mail: drtrajcevska@yahoo.com

Introduction: The latest data by WHO show that 80% of TB cases in Europe are in the countries which have numerous Roma population. The number of Roma in Macedonia is 53 870 (2.66%).

Aim: To fi nd out what is their participation in the total number of TB patients, what is their incidence and are they a risk group for TB and possible reasons for that.

Patients and methods: For this purpose we analyzed data in latest six (6) years with special accent on Roma population with TB (sex, age, incidence).

Results: We had 563 patients with TB in 2007; the incidence was 27.8/100 000 for general population, but the incidence for Roma people was 74.2/100 000. The next year incidence in Roma population was 59.4/100 000 and in general population 23.8/100 000. In 2009 the incidence in Roma population was 42.6/ 100 000 and in general population 23.4/100 000. The next year the incidence in Roma people was 70.5/ 100 000 and in general population 20.8/100 000. In 2011 the incidence in Roma people was 51.9/100 000 and in general population 17.9/100 000. The last year there were 356 regisitrated TB patients in the country with incidence of 17.2/100 000. The incidence of Roma people was 46.4/100 000.

Conclusions: Roma are more vulnerable community. They are risk group for TB because their incidence is three times higher than in general population. Possible reasons for this are: substandard living conditions, lack of education and low rate of employment.

PC-483-01 Association between age and treatment outcomes among tuberculosis patients registered under the Revised National Tuberculosis Control Programme in Uttar Pradesh

K Sharma,¹ S Satyanarayana,² P Memon,¹ A Kumar,² A Pandey,¹ B Kalottee,¹ A Sreenivas,¹ S Tiwari.³ ¹WHO Country Office, Office of the World Health Organization (WHO) Representative in India, New Delhi, ²South-East Asia Office, International Union Against Tuberculosis and Lung Diseases (The Union), New Delhi, ³State Tuberculosis Centre, Directorate of Medical and Health Services, Lucknow, India. e-mail: sharmak@rntcp.org

Background: With increasing life expectancy in In-dia, there has been an increase in elderly population. Since elderly population are a vulnerable group for tuberculosis (TB) and there is paucity of data about the manifestation and outcomes of TB among this group, we undertook a study to describe and com-pare the socio-demographic and clinical characteris-tics and treatment outcomes of elderly (60 years and above) as compared to younger (15 to 59 years) TB patients registered in Revised National Tuberculosis Control Program (RNTCP) and to identify the risk factors associated with poor treatment outcomes among the elderly.

Design/methods: We conducted a retrospective co-hort study involving review of routinely maintained RNTCP records from July to September 2011, in fi ve districts of Western Uttar Pradesh (population: 40 million). World Health Organization (WHO) rec-ommended disease classification and treatment out-come definitions are used by RNTCP. Qualitative data was expressed as proportions, χ^2 test and relative risk along with 95% confidence intervals (CI) were calcu-lated to analyse the association between outcome and potential predictor variables.

Results: Of 2472 TB patients, 821 (33.2%) were el-derly, 1656 (67%) were males 81.7% resided in rural areas and 80% were new cases. Among the elderly TB patients, 22% had unsuccessful (death, default, fail-ure and transfer out) outcomes as against 14.5% in the comparison group ($P < 0.001$). Factors signifi-cantly associated with unsuccessful outcomes among elderly group were living in an urban area (RR = 2.33, 95%CI 1.77–3.07), history of a previous treat-ment (RR = 1.7, 95%CI 1.29–2.23) and non-conver-sion of smear at end of intensive phase (RR = 4.37, 95%CI 2.27–8.42).

Conclusion: Elderly TB patients had poorer treat-ment outcomes as compared to the younger TB pa-tients. This could be due to associated co-morbidities

